Rafael Holdings, Inc. Class B (RFL) News
Filter RFL News Items
RFL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RFL News Highlights
- 500 - Internal server error
- Over the past 28 days, the trend for RFL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about RFL are LAW, CVR and MET.
Latest RFL News From Around the Web
Below are the latest news stories about Rafael Holdings Inc that investors may wish to consider to help them evaluate RFL as an investment opportunity.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Rafael Holdings, Inc. (NYSE:RFL)BALA CYNWYD, PA / ACCESSWIRE / July 27, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors ofRafael Holdings, Inc. ("Rafael Holdings" or the "Company") (NYSE:RFL) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company's agreement to acquire Rafael Pharmaceuticals, Inc. |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates RFL, FCCY, RBNC, GPX; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
RAFAEL (RFL) INVESTIGATION NOTICE - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Rafael Holdings, Inc.WILMINGTON, Del., July 26, 2021 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Rafael Holdings, Inc. (NYSE: RFL) (“Rafael Holdings” or the “Company”) relating to the merger of the Company with Rafael Pharmaceuticals, Inc. (“Rafael Pharmaceuticals”), a privately-held company. The two parties have announced that they |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates SBBP, RFL, CLDB, MPB; Shareholders are Encouraged to Contact the FirmNEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Strongbridge Biopharma plc (NASDAQ: SBBP) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Xeris Pharmaceuticals, Inc. Under the terms of the merger, Strongbridge shareholders will receive 0.7840 shares of the combined company and 1 contingent value right (“CVR”) for each S |
RFL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Rafael Holdings, Inc. (RFL) and Encourages Shareholders to Contact the FirmPHILADELPHIA, July 08, 2021 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Rafael Holdings, Inc. (“Rafael Holdings”) (NYSE: RFL) on behalf of the company’s shareholders. On June 21, 2021, Rafael Holdings announced that it had entered into an agreement to acquire Rafael Pharmaceuticals, Inc. (“Rafael Pharmaceuticals”) in an all-stock transaction. According to the announcement, Rafael Pharmaceuticals’ stockholders are expected to receive shares of Rafael Holdings’ common st |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates RFL, SHSP, ICBK, CLDB; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
INVESTOR ALERT: Kaskela Law LLC Announces Stockholder Investigation of Rafael Holdings, Inc. - RFLPHILADELPHIA, PA / ACCESSWIRE / July 1, 2021 / Kaskela Law LLC announces that it is investigating Rafael Holdings, Inc. ("Rafael Holdings") (NYSE:RFL) on behalf of the company's current stockholders. |
Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)CRANBURY, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced positive outcome from its preplanned interim futility analysis of its pivotal Phase 3 trial (ARMADA 2000) of CPI-613® (devimistat) for relapsed or refractory acute myeloid leukemia (AML) as determined by an independent Data Monitoring Committee (IDMC). The IDMC met on Friday, Jun. 25 and based on the 142 withi |
Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) CongressCRANBURY, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that data on its lead compound, devimistat, has been selected for an oral presentation at the 2021 European Society of Medical Oncology World Gastrointestinal Congress (ESMO), taking place June 30 through July 3, 2021. “We are proud to have our primary clinical investigators present at EMSO to share upda |
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary CancerCompany reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancersCRANBURY, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for CPI-613® (devimistat) for the treatment of biliary cancer. Biliary cancer, which includes gallbladder canc |